See also: Generic Focalin XR
Focalin is a brand name of dexmethylphenidate, approved by the FDA in the following formulation(s):
FOCALIN (dexmethylphenidate hydrochloride - tablet; oral)
Manufacturer: NOVARTIS
Approval date: November 13, 2001
Strength(s): 10MG [RLD][AB], 2.5MG [AB], 5MG [AB]
Has a generic version of Focalin been approved?
A generic version of Focalin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Focalin and have been approved by the FDA:
dexmethylphenidate hydrochloride tablet; oral
Manufacturer: TEVA PHARMS
Approval date: January 29, 2007
Strength(s): 10MG [AB], 2.5MG [AB], 5MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Focalin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method of treating attention deficit disorders with d-threo methylphenidate
Patent 5,908,850
Issued: June 1, 1999
Inventor(s): Zeitlin; Andrew L. & Dariani; Maghsoud M. & Stirling; David I.
Assignee(s): Celgene Corporation
Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.
Patent expiration dates:
Phenidate drug formulations having diminished abuse potential
Patent 6,355,656
Issued: March 12, 2002
Inventor(s): Andrew L.; Zeitlin & Maghsoud M.; Dariani
Assignee(s): Celgene Corporation
Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
Patent expiration dates:
Phenidate drug formulations having diminished abuse potential
Patent 6,528,530
Issued: March 4, 2003
Inventor(s): Andrew L.; Zeitlin & Maghsoud M.; Dariani
Assignee(s): Celgene Corporation
Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
Patent expiration dates:
- December 4, 2015
✓
Drug substance
✓
Drug product
See also...
- Focalin Consumer Information (Drugs.com)
- Focalin Consumer Information (Wolters Kluwer)
- Focalin Consumer Information (Cerner Multum)
- Focalin Advanced Consumer Information (Micromedex)
- Focalin AHFS DI Monographs (ASHP)
- Dexmethylphenidate Consumer Information (Wolters Kluwer)
- Dexmethylphenidate Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Dexmethylphenidate Consumer Information (Cerner Multum)
- Dexmethylphenidate Advanced Consumer Information (Micromedex)
- Dexmethylphenidate Hydrochloride AHFS DI Monographs (ASHP)
